ipharmacenter Consulting services

Dual Special Needs Plans (D-SNPs) are Medicare Advantage plans designed for individuals eligible for both Medicare and Medicaid, offering coordinated coverage that integrates medical, prescription, and supplemental benefits to address complex needs. These plans cover Medicare Parts A, B, and often D alongside Medicaid services like long-term care and behavioral health support, typically with low or no cost-sharing. UnderstandingD-SNPs for Dual Eligibles D-SNPs target "dual el

Eli Lilly has cut out‑of‑pocket prices for its obesity drug Zepbound in the United States, lowering the monthly cost of single‑dose vials for patients who pay cash through its LillyDirect platform in an effort to broaden access to tirzepatide.​   New Zepbound vial pricing and regular prices Under the updated Zepbound Self‑Pay Journey Program on LillyDirect, patients with a valid prescription can now obtain the starter 2.5 mg vial for about 299 dollars per month, down from rou

CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported care for people living with chronic diseases. The first performance period begins July 1, 2026, with applications due by April 1, 2026; applications submitted after that date will be considered for a January 1, 2027 start.​   What is the ACCESS Model? The ACCESS Model tests an outcom

The Centers for Medicare & Medicaid Services (CMS) has proposed new policies for Medicare Advantage (MA) and Medicare Part D plans, aiming to improve quality, boost access, and support innovative benefit designs. The 2027 draft rule details significant changes to the Star Ratings system and invites public comments on how to further modernize Medicare Advantage for both beneficiaries and taxpayers.   Also read: Top 10 pharmaceutical companies by revenues Under these proposed u

Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) in combination with Padcev (enfortumab vedotin) for the perioperative treatment of adults with muscle‑invasive bladder cancer (MIBC) who are ineligible for cisplatin‑based chemotherapy. The regimen includes neoadjuvant therapy before surgery followed by adjuvant treatment after cystectomy. These approvals mark the

CVS Pharmacy Launches Transparent CostVantage Model for Prescription Pricing In a bold move to reshape the retail pharmacy landscape, CVS...

The Institute for Clinical and Economic Review (ICER) recently conducted an assessment of insurance coverage policies for 11 prescription...

CMS Unveils Further Instructions on Initiative Allowing Medicare Beneficiaries to Manage Prescription Drug Expenses via Monthly Payments....

November 09, 2023 Optum Rx Implements Initiatives to Reduce Insulin Expenses Commencing on January 1, 2024, Optum Rx is undertaking...

Cigna Healthcare has unveiled significant enhancements to its service by eliminating the requirement for prior authorization (or...

The Institute for Clinical and Economic Review (ICER) has published its definitive evidence report on gene therapies for Sickle Cell...

CVS Health has unveiled an initiative by launching Cordavis, a wholly-owned subsidiary, to spearhead introducing high-quality biosimilar...